{"id":22974,"date":"2014-04-08T19:49:16","date_gmt":"2014-04-08T23:49:16","guid":{"rendered":"https:\/\/biznews.fiu.edu\/?p=22974"},"modified":"2017-06-21T12:38:16","modified_gmt":"2017-06-21T16:38:16","slug":"weekly-market-wrap-up-april-8-2014","status":"publish","type":"post","link":"https:\/\/biznews.fiu.edu\/2014\/04\/weekly-market-wrap-up-april-8-2014\/","title":{"rendered":"Weekly Market Wrap Up, April 8, 2014"},"content":{"rendered":"

Market Overview:<\/strong><\/p>\n

The NASDAQ Biotech Index and major exchange-traded funds that track biotech firms have suffered most in the last month. Shares for the IBB ETF (Biotechnology Index) have fallen 16% at the news from President Obama to reduce prices for Pharmaceuticals and Biotech companies. The pricing strategies came into question from the House Energy & Commerce Committee to Gilead Sciences for pricing their Hepatitis C drug at $84,000.<\/p>\n

In Economic News, the European Central Bank may implement a negative deposit rate as its next step in monetary easing. A negative deposit rate appears unlikely to spark many sales of euros, the move may even lead to a rise in borrowing costs in the euro area. Lenders might increase interest rates for their clients to compensate for the cost increase created by a negative deposit facility. In Brazil, economists raised their 2014 inflation forecast for the fifth straight week and cut their growth estimates. President Dilma Rousseff\u2019s administration is struggling to spur growth amid above-target inflation. Brazil\u2019s central bank last week lifted the key rate for the ninth straight time after a drought drove up food prices. Growth in Latin America\u2019s largest economy will slow to 2 percent this year from 2.3 percent in 2013, according to central bank estimates.<\/p>\n

 <\/p>\n

Weekly Review:<\/strong><\/p>\n